Care Options
Cancer Vaccine for Dogs: Types, Benefits, Risks
Cancer vaccines for dogs are specialized treatments that stimulate the immune system to fight certain cancers, but they do not prevent or cure every type of cancer.
Key takeaways
Cancer vaccines for dogs are specialized treatments that stimulate the immune system to fight certain cancers, but they do not prevent or cure every type of cancer.
- Cancer vaccines are an option for some dogs already diagnosed with cancer, particularly dogs with oral melanoma.
- The best-known product is ONCEPT, a canine melanoma vaccine designed to help extend survival after the visible cancer has been controlled.
- Other cancer vaccines are being investigated, including personalized vaccines made from a dog's own tumor.
- Their availability and effectiveness depend on the cancer type, disease stage, and supporting research.
What Is a Cancer Vaccine for Dogs?
A cancer vaccine is a form of immunotherapy.
Instead of preventing an infectious disease, as traditional dog vaccines do, it is designed to help the immune system recognize and attack cancer cells.
Cancer cells can sometimes avoid detection by the immune system. A therapeutic cancer vaccine introduces or presents specific proteins associated with those cells so the immune system can develop a response against them.
There are two important distinctions:
- Therapeutic cancer vaccines: Intended to treat dogs that already have cancer, often alongside surgery, radiation, or other treatment.
- Preventive cancer vaccines: Designed to reduce the likelihood of cancer developing in healthy dogs. These remain a research area rather than routine veterinary vaccination.
ONCEPT: The Best-Known Dog Cancer Vaccine
ONCEPT Canine Melanoma Vaccine is a USDA-licensed DNA vaccine used as an additional treatment for dogs with stage II or stage III oral malignant melanoma after local cancer control has been achieved.
It is not a general cancer vaccine. Its approved indication is specifically canine oral melanoma, and it is not intended to replace surgery or radiation treatment.
How ONCEPT works
ONCEPT contains plasmid DNA carrying the gene for human tyrosinase, a protein involved in pigment production. Melanoma cells commonly express tyrosinase.
After vaccination, the dog's cells produce the human version of this protein, stimulating an immune response that can also recognize the corresponding protein on canine melanoma cells. The goal is to help the immune system attack melanoma cells that may remain after the visible tumor has been treated.
Which dogs may qualify?
The vaccine is intended for dogs with:
• Biopsy-confirmed oral malignant melanoma.
• Stage II or stage III disease.
• No remaining visible tumor in the mouth after local treatment.
• Regional lymph nodes that are negative for cancer or have been surgically removed or treated with radiation if involved.
A dog with an untreated, visible oral melanoma generally does not meet the labeled treatment situation. The 2024 melanoma consensus guidelines specifically state that ONCEPT is not indicated for measurable, visible disease.
How is ONCEPT administered?
The initial treatment consists of four vaccinations given at two-week intervals, followed by booster vaccinations every six months. A veterinarian administers the vaccine using a specialized transdermal delivery device.
Treatment requires follow-up appointments, and the veterinary oncology team monitors the dog's condition and response over time.
Does the Cancer Vaccine Actually Work?
The evidence for ONCEPT is encouraging in some studies but not conclusive across all dogs with melanoma.
A prospective clinical study involving dogs with stage II and III oral melanoma found longer survival among vaccinated dogs than among a historical comparison group. More than half of the vaccinated dogs survived beyond 437 days, while the historical comparison group had a median survival of 324 days.
However, two retrospective studies did not demonstrate a clear survival benefit. The consensus review noted that local tumor control had not been adequately achieved in those studies, which may have affected the results.
The practical interpretation is:
• ONCEPT may provide additional benefit when oral melanoma has been adequately controlled locally.
• It is not a proven cure for melanoma.
• It cannot guarantee that cancer will not spread or return.
• It should not replace surgery, radiation, staging, or other recommended treatment.
• Individual outcomes vary, and the available evidence does not reliably predict which dog will benefit.
The 2026 AAHA oncology guidelines also emphasize that veterinary immunotherapy remains a developing field, with limited options and some treatments discontinued after larger studies identified safety or effectiveness problems.
Another Cancer Treatment Involving a Vaccine: ELIAS
Dogs with osteosarcoma, a type of bone cancer, may have another option called ELIAS Cancer Immunotherapy (ECI).
This is different from ONCEPT because it combines a personalized cancer vaccine with adoptive T-cell therapy.
The treatment uses tissue from the dog's own tumor to prepare a personalized vaccine. The vaccine stimulates immune recognition of the cancer, after which the dog's immune cells are collected, activated outside the body, and returned through an infusion.
Which dogs may qualify?
ECI is a USDA-licensed autologous prescription product for canine osteosarcoma. Its intended treatment population includes dogs with appendicular osteosarcoma, meaning cancer affecting a limb, without evidence of lung metastasis on chest imaging.
An important consideration is that the cancer tissue must be collected during surgery to prepare the personalized treatment. Owners should discuss ECI with an appropriately trained veterinary oncologist before the affected limb is amputated. A dog that has already undergone amputation cannot receive this treatment under the described protocol because the required tumor tissue is no longer available.
Is ELIAS just a vaccine injection?
No. It is a multi-step treatment involving:
• Collection and processing of tumor tissue.
• Preparation and administration of personalized cancer vaccines.
• Collection of the dog's immune cells through apheresis.
• Laboratory activation and expansion of T cells.
• Reinfusion of the activated immune cells.
The entire protocol is required. Receiving only the vaccine portion is not considered the complete ELIAS treatment. It must be administered through an authorized, appropriately trained veterinary oncology team.
Are Other Cancer Vaccines Being Developed for Dogs?
Yes.
Researchers are investigating additional ways to use the immune system against canine cancers, including personalized vaccines and vaccines targeting proteins found on cancer cells.
Personalized tumor vaccines
An autologous cancer vaccine is made using tissue from the dog's own tumor. The goal is to expose the immune system to cancer-specific material so it can recognize and attack remaining cancer cells.
These treatments are not interchangeable with ONCEPT. Their availability, regulatory status, and supporting evidence depend on the specific product and cancer. Many personalized vaccine approaches remain investigational.
Experimental cancer vaccine trials
Veterinary research is also exploring new vaccine technologies, including approaches for melanoma, bone cancer, and other aggressive tumors.
A clinical trial may offer access to a treatment that is not routinely available, but participation does not guarantee that the vaccine will work. Eligibility can depend on the cancer diagnosis, stage, previous treatment, overall health, and availability of tumor tissue.
Can a Cancer Vaccine Prevent Cancer in Healthy Dogs?
There is no universal cancer-prevention vaccine available as routine veterinary care for healthy dogs.
The established treatments discussed above are intended for particular cancers that have already been diagnosed.
Preventive cancer vaccination is a separate area of research. It should not be confused with ordinary puppy and adult vaccinations, which protect against infectious diseases rather than cancer.
Regular veterinary examinations remain important because early identification and diagnosis can help determine which treatment options are appropriate.
How to Find Out Whether a Dog Qualifies for a Cancer Vaccine
The most important factors are the exact cancer diagnosis and its stage.
A dog should not be considered eligible based on the presence of a lump or suspected cancer alone.
1. Confirm the cancer diagnosis
A veterinarian may recommend biopsy and histopathology to identify the tumor type. Melanomas can vary in pigmentation, and some require additional laboratory examination to confirm the diagnosis.
2. Determine the cancer stage
Staging helps establish whether the cancer has spread and whether local treatment can control the original tumor.
Depending on the cancer, evaluation may include:
• Examination of regional lymph nodes.
• Chest imaging to look for lung metastases.
• Imaging of the primary tumor.
• Assessment of whether the tumor can be surgically removed.
3. Discuss local cancer treatment
For canine melanoma, surgery is an important treatment for controlling the primary tumor. Radiation may also be appropriate, particularly when complete surgical removal is not possible.
For ONCEPT, adequate local disease control is particularly important before vaccination.
4. Request a veterinary oncology consultation
A veterinary oncologist can determine whether ONCEPT, ELIAS, another immunotherapy, or a clinical trial is appropriate.
For possible ELIAS treatment, consultation must occur before amputation because the tumor tissue is needed to prepare the personalized vaccine.
5. Compare the expected benefits and limitations
Before agreeing to treatment, establish:
• Whether the product is USDA-licensed or investigational.
• Whether published studies involve the same cancer type and stage.
• Whether the treatment has demonstrated longer survival or only an immune response.
• Whether surgery, chemotherapy, or radiation is still necessary.
• What side effects and follow-up appointments to expect.
• Which treatment costs are covered and which are the owner's responsibility.
Side Effects and Safety of Cancer Vaccines for Dogs
Cancer vaccines can cause reactions, and the risks differ between products.
ONCEPT side effects
The USDA safety study recorded the following events after vaccination:
• Injection-site pain.
• Bruising and swelling.
• Injection-site itching or irritation.
• Fever.
• Lethargy.
• Reduced appetite.
• Vomiting.
These were reported observations during safety monitoring and do not establish that every event was caused by the vaccine.
A dog developing new or worsening symptoms after vaccination should be assessed by the treating veterinary team. Difficulty breathing, collapse, or rapidly developing swelling requires emergency veterinary attention.
ELIAS treatment considerations
ELIAS involves more than vaccination. It includes tumor removal, personalized vaccine preparation, immune-cell collection, laboratory processing, and cell reinfusion.
Because of these additional procedures, the oncology team should explain the treatment risks, restrictions, monitoring requirements, and expected recovery before treatment begins.
How Much Does a Cancer Vaccine for Dogs Cost?
There is no single price for canine cancer vaccines.
The total expense depends on the product, cancer diagnosis, specialist fees, tumor sampling, surgery, laboratory preparation, and follow-up care.
ELIAS can involve several providers, including a veterinary oncologist, surgeon, and cell-therapy service. Their fees can vary.
Before starting treatment, request an itemized estimate covering:
• Initial examination and cancer staging.
• Biopsy and laboratory testing.
• Vaccine preparation and administration.
• Surgery or radiation, if needed.
• Additional immune-cell procedures.
• Follow-up examinations and monitoring.
For clinical trials, ask which study-related expenses are covered and which remain the owner's responsibility.
Frequently asked questions
Is there an FDA-approved cancer vaccine for dogs?
Veterinary biological products, including canine cancer vaccines, are regulated by the USDA rather than the FDA. ONCEPT is USDA-licensed, and ELIAS is distributed under a USDA autologous prescription product license.
Does ONCEPT cure cancer in dogs?
No. ONCEPT is an additional treatment intended to stimulate an immune response against canine melanoma. It does not guarantee that cancer will disappear, stop spreading, or never return.
Can a dog receive the melanoma vaccine if cancer has spread?
ONCEPT is labeled for stage II or III oral melanoma after local disease control. It is not indicated for visible, measurable cancer. A dog with metastatic disease needs an individualized treatment assessment.
Is the ELIAS vaccine the same as ONCEPT?
No. ONCEPT is a DNA vaccine for certain dogs with oral melanoma. ELIAS combines a personalized vaccine made from the dog's tumor with activated T-cell therapy for canine osteosarcoma.
Are cancer vaccines available for dogs with lymphoma or hemangiosarcoma?
Research is investigating additional immunotherapy approaches for different cancers. However, ONCEPT is not a general cancer treatment, and the suitability of other vaccines depends on their specific indications and evidence. A veterinary oncologist can identify relevant treatment studies.
Can a healthy dog receive a cancer vaccine to prevent tumors?
There is no universal preventive cancer vaccine in routine veterinary practice. Cancer-prevention vaccination remains separate from established therapeutic cancer vaccines.
Should a dog receive chemotherapy or surgery along with a cancer vaccine?
Sometimes. Cancer vaccines are often intended to complement other treatments rather than replace them. For oral melanoma, adequate local tumor control is particularly important when considering ONCEPT. The appropriate combination depends on the cancer and its stage.
Editorial standards
Who wrote this guide
Written by VetWayfinder Editorial Team.
Every factual statement is tied to a cited source listed below. Report an error through the corrections page.
Sources
Each source supports at least one factual statement in this guide.
